Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Liabilities (2016 - 2025)

Northwest Biotherapeutics' Total Liabilities history spans 16 years, with the latest figure at $128.9 million for Q4 2025.

  • Quarterly results put Total Liabilities at $128.9 million for Q4 2025, up 21.9% from a year ago — trailing twelve months through Dec 2025 was $128.9 million (up 21.9% YoY), and the annual figure for FY2025 was $128.9 million, up 21.9%.
  • Total Liabilities for Q4 2025 was $128.9 million at Northwest Biotherapeutics, up from $125.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $385.7 million in Q1 2021 to a low of $64.1 million in Q2 2023.
  • The 5-year median for Total Liabilities is $117.7 million (2022), against an average of $146.0 million.
  • The sharpest move saw Total Liabilities soared 773.03% in 2021, then plummeted 68.52% in 2022.
  • Year by year, Total Liabilities stood at $164.2 million in 2021, then fell by 16.93% to $136.4 million in 2022, then plummeted by 45.06% to $74.9 million in 2023, then soared by 41.09% to $105.7 million in 2024, then increased by 21.9% to $128.9 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $128.9 million, $125.9 million, and $116.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.